

Veterinarians and pet owners have a new therapy to help keep their canine and feline friends comfortable and active in the face of osteoarthritis (OA) pain.



Librela for dogs and Solensia for cats, the first injectable monthly antibody therapeutics for OA pain from Zoetis, are breakthroughs in OA pain management. Surveys with European veterinarians report high satisfaction with these products and provide insights into patient selection and utilisation since launch in 2021 in Europe.



LIBRELA AND SOLENSIA TARGET NERVE GROWTH FACTOR (NGF) TO RELIEVE OA PAIN FOR DOGS AND CATS

Librela® (bedinvetmab) and Solensia® (frunevetmab) represent the first new OA pain medication class outside the prostaglandin pain pathway in over 20 years. These once monthly subcutaneous injectable therapeutics work differently than nonsteroidal anti-inflammatory drugs (NSAIDs) by targeting a key player in the pain pathway: NGF.¹

When Librela or Solensia binds to NGF, it lowers the amount of NGF able to bind to its receptors in the peripheral nervous system, which decreases the amount of pain signal from the affected joint to the brain. These drugs function like naturally occurring antibodies and are eliminated via normal protein degradation pathways in the same way, with minimal involvement of the liver or kidneys.²

In clinical trials, OA pain was effectively alleviated for 1 month and was well tolerated³⁻⁵:

- Dogs receiving Librela experienced increased mobility and decreased pain after the first injection³
- Cats receiving Solensia experienced improved mobility, comfort, and well-being^{4,5}

Librela and Solensia are designed to improve compliance by putting OA pain treatment in the veterinarian's hands as a monthly injection delivered in clinic. They are included in [The American Animal Hospital Association](#) and [WSAVA](#) guidelines as first-line therapy for dogs and cats with OA pain to help provide relief and improve quality of life.^{6,7}


VETERINARIANS' EXPERIENCE WITH LIBRELA AND SOLENSIA IN EUROPE

To help understand veterinarians' early experience with the use of Librela and Solensia, Zoetis conducted multiple market research studies.⁸⁻¹³ Veterinarians were asked about their perceptions of efficacy, safety, and cost, as well as compliance and satisfaction. Feedback on overall satisfaction and perceptions of cost was also sought from pet owners.^{10,13}

The studies were masked, with the study sponsor (Zoetis) unknown to participants. They included⁸⁻¹³:

- Post-launch surveys of >1000 veterinarians
- Chart pull studies describing nearly 4000 dogs and cats

These studies provide valuable insights into veterinarians' use of Librela and Solensia in clinical practice and their application in various canine and feline populations. High overall satisfaction ratings were received for both Librela and Solensia (average 8 out of 10).^{8,12}



LIBRELA—A NEW ERA IN OA PAIN MANAGEMENT


Librela launched in Europe in February 2021, and as of November 2022, over 4.6 million doses had been delivered.

Veterinarians report broad use of Librela across many types of dogs with OA pain, including those:

- Aged 2 to 20 years (average age, 11 years)⁹
- With mild, moderate, and severe disease^{8,9}
- Newly and previously diagnosed with OA pain, many with comorbidities at the start of treatment^{8,9}



VETERINARIANS REPORTED HIGHER LEVELS OF SATISFACTION WITH LIBRELA THAN WITH OTHER OA PAIN MEDICATIONS⁸



Dog owners also reported a high level of satisfaction, with 64% rating Librela better than previous medications.¹⁰ Compliance with monthly dosing was high, ranging from 88% to 100% over the study period.⁹ The cost of Librela was rated as inexpensive, a good value, or expensive but reasonable by 88% of dog owners.¹⁰

“ As a vet for nearly 30 years now...we as a profession are seeing amazing results. As the owner of a 6 year old retriever with severe elbow arthritis I am also immensely grateful....[S]ince we started Librela he is happy and active again. ”
— Veterinarian, UK

SOLENSIA—HELPING MORE CATS GET RELIEF FROM OA PAIN


Solensia launched in Europe in March 2021, and as of November 2022, 1.5 million doses had been delivered.

Veterinarians report broad use of Solensia across many types of cats with OA pain, including those¹²:

- Aged 1 to 19 years (average age, 11 years)
- With mild, moderate, and severe disease
- Newly and previously diagnosed with OA pain, many with comorbidities at the start of treatment



VETERINARIANS REPORTED HIGHER LEVELS OF SATISFACTION WITH SOLENSIA THAN WITH OTHER OA PAIN MEDICATIONS¹¹




Cat owners also reported a high level of satisfaction with Solensia, with 66% rating it better than previous medications.¹³ Compliance with monthly dosing was high, ranging from 87% to 100% over the study period.¹² The cost of Solensia was rated as inexpensive, a good value, or expensive but reasonable by 85% of cat owners.¹³

“ Solensia is a really interesting and exciting development because I think it opens up a new channel for treatment which gets around some of the problems that exist. ”
— Martha Cannon, BA, VetMB, DSAM(Fel)

LEARN MORE ABOUT LIBRELA AND SOLENSIA

Zoetis is committed to helping veterinary professionals and pet owners provide relief for dogs and cats with OA pain. Learn more about [Librela](#) and [Solensia](#) today



Approved labeling for registered products can be different in various countries around the world; and not all products are approved for use in every country around the world. The information featured in this piece is based on approved product labeling in countries in which it is approved. Consult your local Zoetis representative in the country where you practice for additional product information. This advertorial was approved for use in the UK.

References: 1. Epstein ME. Anti-nerve growth factor monoclonal antibody: a prospective new therapy for canine and feline osteoarthritis. *Vet Rec.* 2019;184(1):20-22. 2. Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. *Clin Pharmacokinet.* 2010;49(8):493-507. 3. Corral MJ, Moyaert H, Fernandes T, et al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. *Vet Anaesth Analg.* 2021;48(6):943-955. 4. Gruen ME, Myers JAE, Lascelles BD. Efficacy and safety of an anti-nerve growth factor antibody (frunvetmab) for the treatment of degenerative joint disease-associated chronic pain in cats: a multisite pilot field study. *Front Vet Sci.* 2021;8:610028. doi: 10.3389/fvets.2021.610028. 5. Gruen ME, Myers JAE, Tena J-KS, Becskei C, Cleaver DM, Lascelles BD. Frunvetmab, a feline anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats. *J Vet Intern Med.* 2021;35(6):2752-2762. 6. Monteiro BP, Lascelles BD, Murrell J, Robertson S, Steagall PVM, Wright B. 2022 WSAVA guidelines for the recognition, assessment and treatment of pain. *J Small Anim Pract.* 2022; British Small Animal Veterinary Association. 7. Gruen ME, Lascelles BD, Colleran E, Johnson J, Marcellin-Little D. 2022 AAHA pain management guidelines for dogs and cats. *J Am Anim Hosp Assoc.* 2022;25(2):55-76. 8. Study Report: 6 Countries. Market research conducted for Zoetis by Bio'Sat. Data on file. Zoetis Inc., June 2021. 9. European Librela Chart Pull Study Using Patient Record Forms. FMR Global Health Report. Market research conducted for Zoetis. Data on file. Zoetis Inc., December 2021. 10. Librela Canine Anti-NGF Market Dynamics and Forecasting Analysis. Market research conducted for Zoetis by Foster Rosenblatt. Data on file. Zoetis Inc., February 2022. 11. Post Launch Tracker Study Report: Wave 2. Market research conducted for Zoetis by Bio'Sat. Data on file. Zoetis Inc., January 2022. 12. European Solensia Chart Pull Study Using Patient Record Forms. Market research conducted for Zoetis by FMR Global Health. Data on file. Zoetis Inc., June 2022. 13. Feline anti-NGF. European Vet and Pet Owner Study. Market research conducted for Zoetis by Foster Rosenblatt. Data on file. Zoetis Inc., December 2022.

Librela[®] contains Bedinvetmab. Librela is licensed for the alleviation of pain associated with osteoarthritis in dogs. Solensia[®] contains Frunvetmab. Solensia is licensed for the alleviation of pain associated with osteoarthritis in cats. **POM-V** For further information please see the product's SPC or contact Zoetis UK Ltd, Birchwood Building, Springfield Dr, Leatherhead, KT22 7LP • www.zoetis.co.uk • Customer Support: 0345 300 8034 or customersupportUK@zoetis.com • Use medicines responsibly (www.noah.co.uk/responsible). Date of preparation: June 2023. MM-26509

